Adequacy of safety data reporting in randomized clinical trials comparing coxibs with non selective NSAIDs

Epitheorese Klinikes Farmakologias kai Farmakokinetikes

Volumn 23, Issue 1, 2005, Pages 42-43

  Yiannakopoulou, E ^a   Damianou, Ch ^b   Bamia, Ch ^a   Papadopulos, J S ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Coxibs; Meta analysis; Non steroidal anti inflammatory agents; Safety data reporting

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; COCHRANE LIBRARY; CONFERENCE PAPER; DATA ANALYSIS; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; MEDLINE; META ANALYSIS; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 14744290832     PISSN: 10116575     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Verburg KM, Maziasz TJ, Weiner E et al. Cox-2 specific inhibitors: Definition of anew therapeutic concept. Am J Ther 8:49-64 (2001)
2. Gottlieb S. FDA refuses companies' request to drop ulcer warning. BMJ 322:385 (2001)
3. Krum H, Liew D et al. Cardiovascular effects of selective cyclooxygenase-2- inhibitors. Expert Rev Cardiovasc Ther 2:265-70 (2004)
4. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function. Focus on cyclooxygenase-2-selective inhibition. Am J MedS 107:655-715 (1999)